B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 11.8 NOK -5.9% Market Closed
Market Cap: 479.2m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

P/OCF
Price to OCF

-3.3
Current
-421.8
Median
21.6
Industry
Higher than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-3.3
=
Market Cap
461.2m NOK
/
Operating Cash Flow
-139m NOK
All Countries
Close
Market Cap P/OCF
NO
Bergenbio ASA
OSE:BGBIO
461.2m NOK -3.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -237 521.5
US
Abbvie Inc
NYSE:ABBV
325.5B USD 19.7
US
Amgen Inc
NASDAQ:AMGN
150.4B USD 20.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.9B USD -142.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 11.5
US
Epizyme Inc
F:EPE
94.1B EUR -473.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 31.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.7B USD 19.6
US
Seagen Inc
F:SGT
39.3B EUR -76.5
NL
argenx SE
XBRU:ARGX
34.6B EUR -139.8
 
NO
B
Bergenbio ASA
OSE:BGBIO
Average P/OCF: 20.6
Negative Multiple: -3.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -237 521.5
US
Abbvie Inc
NYSE:ABBV
19.7
US
Amgen Inc
NASDAQ:AMGN
20.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -142.4
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -473.6
AU
CSL Ltd
ASX:CSL
31.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -76.5
NL
argenx SE
XBRU:ARGX
Negative Multiple: -139.8

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A

See Also

Discover More